Abstract 9178: Cell-Based Prostacyclin Gene Therapy Prevents Pulmonary Arterial Hypertension

Objectives: Intravenous prostacyclin is approved for the treatment of pulmonary arterial hypertension (PAH). However, it has limitations of a short half-life, the permanent placement of an intraven...